The Dynamic Trial: Is it the Right Option for You?

It’s no secret that conventional clinical trial design leaves ample room for improvement in oncology. Just 1 in 3 clinical trials for cancer drugs successfully advances from Phase II to Phase III. Among those, only about half make it to an approved drug.

Given the urgency of cancer drug development, isn’t there a way to be more efficient—and cost-effective, too?

The FDA thinks so—as evidenced by a series of 2018 guidance documents that call for the need to modernize trial structure through adaptive design:

By using a change-as-you-go strategy that evolves as new data emerges, adaptive design saves time, money and resources. But how can you get there?

Enter TD2’s Dynamic Trial, an adaptive approach to trial design that folds in more exploratory cohorts for faster insights earlier in the development process. In a standard design, those cohorts wouldn’t come into play until Phase II. But in the Dynamic Trial, they’re the very factors that inform Phase II design.

Traditional Phase 1 Trail Design Model

The Dynamic Trial Design Model

Dynamic Trial Benefits:

Challenges of Dynamic Trial:

3 Signs You Should Consider the Dynamic Trial

The Dynamic Trial offers time and cost savings across-the-board, but it’s not right for every investigation into every drug. If these three indicators apply to you, the benefits might outweigh the challenges for optimum results:

Ready to Get Started?

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, we provide start-to-finish support with trial strategy, design and execution for faster go-to-market potential. Contact us today to get started!